Key result
Current pharmacotherapies provide only moderate efficacy for atherogenic dyslipidemia in T2D and metabolic syndrome.
Why the study?
Current treatment options for managing atherogenic dyslipidemia in patients with metabolic syndrome or type 2 diabetes mellitus are limited and only moderately effective.
This review emphasizes the need for multifactorial treatment strategies, including combination pharmacotherapies and novel agents, to effectively manage atherogenic dyslipidemia in patients with metabolic syndrome or T2DM.
Multifactorial lifestyle plus pharmacologic strategies remain essential in MS and T2DM; leaves open optimal sequencing amid newer agents.
J Clin Hypertens (Greenwich). 2009;11:520-527. (c)2009 Wiley Periodicals, Inc.Strategies for the effective management of cardiovascular risk factors in patients with the metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM) are essential to help reduce cardiovascular morbidity and mortality. Treatment strategies should be multifactorial and include the promotion of therapeutic lifestyle changes, as well as pharmacologic therapies to treat individual risk factors according to current guidelines. In an accompanying article, the importance of atherogenic dyslipidemia as a risk factor for the development of cardiovascular disease in patients with MS or T2DM was highlighted. Current treatment options for managing this characteristic form of atherogenic dyslipidemia are limited and tend to be only moderately effective. The focus of this review is the current pharmacotherapies available for the management of atherogenic dyslipidemia in patients with the MS or T2DM, highlighting the rationale for combining available treatments. Novel strategies currently in clinical development are also discussed.
No takes yet. Share an insight, caveat, or question.
Ginsberg et al. (2009) conducted a review in Metabolic syndrome or type 2 diabetes mellitus with atherogenic dyslipidemia. Pharmacotherapies for atherogenic dyslipidemia was evaluated. Current pharmacotherapies for managing atherogenic dyslipidemia in patients with metabolic syndrome or type 2 diabetes are limited and tend to be only moderately effective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: